Author

H. Osumi

h-index 20 View on Semantic Scholar

We have 3 of 202 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

BACKGROUND Fruquintinib has demonstrated survival benefits in patients with previously treated metastatic colorectal cancer (mCRC) in phase III trials. However, real-world data in Japanese patients remain limited. This study evaluated the effectiveness and safety of fruquintinib in routine clinical practice. METHODS...

Shohei Udagawa, Chihiro Ishizuka, H. Osumi et al. · International Journal of Cli... · 0 citations

Open access Aug 2026

Prognostic impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer

Summary Post-treatment alterations in circulating tumor DNA (ctDNA) hold potential for refining treatment strategies in metastatic colorectal cancer (mCRC). In this multi-institutional study of 1,391 patients from the SCRUM-Japan GOZILA platform, we evaluated the prognostic significance of post-treatment rat sarcoma vi...

H. Osumi, E. Shinozaki, Yoshiaki Nakamura et al. · iScience · 0 citations

Case report Open access Jul 2026

Single-center Experience with Comprehensive Genomic Profiling Using Circulating Tumor DNA for Metastatic Colorectal Cancer

Re-evaluation of molecular profiles using ctDNA enabled the exploratory identification of NeoRAS wild-type patients, who could potentially benefit from anti-EGFR therapy, in a real-world setting.

K. Ito, K. Kataoka, Yoshiko Muroi et al. · Journal of the Anus Rectum a... · 0 citations